AU2005279590A1 - Vaccine composition against hepatitis C virus - Google Patents

Vaccine composition against hepatitis C virus

Info

Publication number
AU2005279590A1
AU2005279590A1 AU2005279590A AU2005279590A AU2005279590A1 AU 2005279590 A1 AU2005279590 A1 AU 2005279590A1 AU 2005279590 A AU2005279590 A AU 2005279590A AU 2005279590 A AU2005279590 A AU 2005279590A AU 2005279590 A1 AU2005279590 A1 AU 2005279590A1
Authority
AU
Australia
Prior art keywords
virus
vaccine composition
composition against
against hepatitis
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2005279590A
Other versions
AU2005279590B2 (en
Inventor
Nelson Acosta Rivero
Liz Alvarez-Lajonchere Ponce De Leon
Santiago Duenas Carrera
Maria Guirola Tsibulova
Gillian Martinez Donato
Alexis Musacchio Lasa
Gretel Sardinas Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of AU2005279590A1 publication Critical patent/AU2005279590A1/en
Application granted granted Critical
Publication of AU2005279590B2 publication Critical patent/AU2005279590B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2005279590A 2004-09-03 2005-08-29 Vaccine composition against hepatitis C virus Ceased AU2005279590B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2004-0189 2004-09-03
CU20040189A CU23496A1 (en) 2004-09-03 2004-09-03 VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C
PCT/CU2005/000005 WO2006024240A2 (en) 2004-09-03 2005-08-29 Vaccine composition against hepatitis c virus

Publications (2)

Publication Number Publication Date
AU2005279590A1 true AU2005279590A1 (en) 2006-03-09
AU2005279590B2 AU2005279590B2 (en) 2010-12-16

Family

ID=40262832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005279590A Ceased AU2005279590B2 (en) 2004-09-03 2005-08-29 Vaccine composition against hepatitis C virus

Country Status (15)

Country Link
US (1) US20080138360A1 (en)
EP (1) EP1785143B1 (en)
JP (1) JP4917539B2 (en)
KR (1) KR101245154B1 (en)
CN (1) CN101043902B (en)
AR (1) AR052639A1 (en)
AU (1) AU2005279590B2 (en)
BR (1) BRPI0514884A (en)
CA (1) CA2577918C (en)
CU (1) CU23496A1 (en)
HK (1) HK1109069A1 (en)
MX (1) MX2007002659A (en)
RU (1) RU2351363C2 (en)
WO (1) WO2006024240A2 (en)
ZA (1) ZA200701674B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine formulations
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CA2698397C (en) 2007-09-18 2018-03-27 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104911154A (en) * 2008-08-08 2015-09-16 武田疫苗股份有限公司 Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
JP6208659B2 (en) 2011-07-11 2017-10-04 タケダ ワクチン，インコーポレイテッド Parenteral norovirus vaccine formulation
RU2510998C2 (en) * 2012-08-01 2014-04-10 Николай Николаевич Грановский VACCINE OF VIRUS-LIKE PARTICLES CONTAINING ALL HEPATITIS C VIRUS STRUCTURAL ANTIGENS, AND METHOD FOR PREPARING IT IN Hansenula polymorpha YEAST
CU24112B1 (en) 2012-11-05 2015-08-27 Ct De Ingeniería Genética Y Biotecnología CHEMICAL VACCINAL ANTIGENS AGAINST HEPATITIS C VIRUS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
DE69533167D1 (en) * 1994-10-05 2004-07-22 Apollon Inc VACCINE AGAINST HEPATITIS B AND C VIRUS
CA2269097C (en) * 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
ATE402715T1 (en) * 1999-11-19 2008-08-15 Csl Ltd HCV VACCINE COMPOSITIONS
AU2002225895A1 (en) * 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030021805A1 (en) * 2001-05-29 2003-01-30 Barber Glen N. Generation of HCV-like particles and chimeric HCV virus
CU23244A1 (en) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech VACCINATION FORMULATION POTENTIATED BY THE COMBINATION OF A DNA WITH AN ANTIGEN
DE10143490C2 (en) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Recombinant MVA with the ability to express HCV structural antigens

Also Published As

Publication number Publication date
RU2351363C2 (en) 2009-04-10
MX2007002659A (en) 2007-05-16
BRPI0514884A (en) 2008-06-24
EP1785143B1 (en) 2015-03-04
KR20070057861A (en) 2007-06-07
EP1785143A2 (en) 2007-05-16
AU2005279590B2 (en) 2010-12-16
AR052639A1 (en) 2007-03-28
CA2577918C (en) 2013-05-28
JP2008511556A (en) 2008-04-17
ZA200701674B (en) 2008-08-27
US20080138360A1 (en) 2008-06-12
JP4917539B2 (en) 2012-04-18
RU2007112117A (en) 2008-10-10
CA2577918A1 (en) 2006-03-09
CN101043902B (en) 2012-04-18
CN101043902A (en) 2007-09-26
HK1109069A1 (en) 2008-05-30
WO2006024240A2 (en) 2006-03-09
CU23496A1 (en) 2010-02-23
WO2006024240A3 (en) 2006-06-01
KR101245154B1 (en) 2013-03-19

Similar Documents

Publication Publication Date Title
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
EP1684787A4 (en) Hepatitis c virus inhibitors
EP1684745A4 (en) Hepatitis c virus inhibitors
EP1603590A4 (en) Influenza virus vaccine
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
HK1138297A1 (en) Human antibodies against hepatitis c virus (hcv) uses thereof (hcv)
HK1223968A1 (en) Rabies virus and compositions and methods thereof
HK1123055A1 (en) Hepatitis c virus nucleic acid vaccine
IL189329A0 (en) Vaccination against dengue virus infection
AU2003254594A1 (en) Methods and compositions for detecting sars virus and other infectious agents
IL194920A0 (en) Hepatitis c virus infection biomarkers
AU2005279590A1 (en) Vaccine composition against hepatitis C virus
EP1871411A4 (en) Expressing hepatitis b virus surface antigen for vaccine preparation
AU2003206862A1 (en) Hepatitis b vaccines
AU2003294757A1 (en) Formulations useful against hepatitis c virus infections
GB0416487D0 (en) Modified virus
AU2003229474A1 (en) Methods and compositions for detecting sars virus
EP1907537A4 (en) Paramyxoviridae virus preparations
AU2003301865A1 (en) Epitopes of hepatitis c virus
ZA200802176B (en) Vaccination against dengue virus infection
AU2004904920A0 (en) Hepatitis C Virus Epitopes
AU2004903497A0 (en) Hepatitis B virus polymerase
GB0421916D0 (en) Hepatitis C virus replication system
AU2005902198A0 (en) Synthetic hepatitis C vaccines
AU2005900928A0 (en) Modified vaccine composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired